Aptevo Therapeutics Inc (APVO) Stock Price, Quote & News

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 838 0500

Fax: 206 838 0503

Website: aptevotherapeutics.com

Address:

2401 4th Avenue, Suite 1050, Seattle, United States

FadG Mar. 20 at 4:08 PM

$APVO as somebody who was invested with a huge position (kept on adding over 2 years time), I still lost 99%. Now, almost two years of exit, I see that their entire pipeline is changed and that still stuck at phase 1.... fkkk.... in the meantime, heard Marvin White retired. Crazy rip-off... individual stock holders have been financing their salaries for years and years

0 · Reply

MicrocapCowboy Mar. 18 at 5:39 PM

$APVO if you have any visibility into the statistical milestones used to either halt a trial or advance it to the next phase, you can easily assess the "go" or "no-go" decision for Mipletamig is pending.

0 · Reply

MOONMAN22 Mar. 17 at 6:46 PM

$APVO Holding & accumulating.

0 · Reply

MicrocapCowboy Mar. 17 at 1:20 PM

$APVO we are close...oh so close

0 · Reply

BLOCKS77 Mar. 13 at 10:26 PM

$APVO

0 · Reply

AZOZ Mar. 13 at 1:07 PM

$APVO Oversold swing idea 💡

0 · Reply

Traildog19 Mar. 12 at 1:23 PM

$APVO is the Big Pharma Medical/ industrial complex , with the assistance of MM’s and Hedge funds trying to force price down to eradicate the meager amount of existing shares & warrants via r/s or some other mechanism such as BK, in order to purchase their assets at auction post BK? Or Market Maker (MM) Strategies: Theories suggest MMs may suppress prices during an "accumulation phase" to acquire shares at the lowest possible cost before a planned reversal or acquisition.

1 · Reply

zzzzzzzzzzzxxx Mar. 12 at 8:25 AM

$TAOP shorting both $APVO welcome mo

0 · Reply

ShadowSnake Mar. 11 at 8:36 PM

$APVO was there an offering I missed?

1 · Reply

BLOCKS77 Mar. 11 at 7:21 PM

$APVO Holding. Avg down. LFG.

0 · Reply

Aptevo to Participate in March 2026 Conferences

Mar 10, 2026, 8:05 AM EDT - 11 days ago

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Feb 3, 2026, 8:05 AM EST - 6 weeks ago

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Jan 9, 2026, 8:05 AM EST - 2 months ago

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Dec 26, 2025, 8:05 AM EST - 3 months ago

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

Dec 9, 2025, 8:05 AM EST - 3 months ago

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

Nov 10, 2025, 8:05 AM EST - 4 months ago

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Nov 6, 2025, 8:05 AM EST - 4 months ago

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Oct 8, 2025, 8:20 AM EDT - 5 months ago

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Sep 16, 2025, 8:30 AM EDT - 6 months ago

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Sep 4, 2025, 8:45 AM EDT - 7 months ago

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aug 13, 2025, 8:05 AM EDT - 7 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 11, 2025, 8:05 AM EDT - 7 months ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Jun 20, 2025, 11:30 AM EDT - 9 months ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 8:55 AM EDT - 9 months ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:01 AM EDT - 9 months ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Jun 18, 2025, 1:34 PM EDT - 9 months ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 11:37 AM EDT - 9 months ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 10:52 AM EDT - 9 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 8:01 AM EDT - 9 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 13, 2025, 8:05 AM EDT - 10 months ago

Aptevo Participating in the BIO International Convention

May 22, 2025, 8:05 AM EDT - 10 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 15, 2025, 8:05 AM EDT - 11 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 8, 2025, 8:45 AM EDT - 11 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Apr 22, 2025, 4:05 PM EDT - 11 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 11 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 1 year ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 20, 2025, 8:35 AM EDT - 1 year ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 18, 2025, 8:05 AM EDT - 1 year ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 6, 2025, 8:00 AM EST - 1 year ago

Aptevo to Participate in March Conferences

Feb 15, 2025, 6:59 PM EST - 1 year ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 14, 2025, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Jan 15, 2025, 8:00 AM EST - 1 year ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Dec 12, 2024, 12:50 PM EST - 1 year ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 9:00 AM EST - 1 year ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 4, 2024, 8:35 AM EST - 1 year ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Nov 29, 2024, 9:55 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 26, 2024, 8:35 AM EST - 1 year ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 22, 2024, 8:35 AM EST - 1 year ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 20, 2024, 8:35 AM EST - 1 year ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 11, 2024, 8:15 AM EST - 1 year ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 7, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

May 14, 2024, 8:05 AM EDT - 2 years ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

FadG Mar. 20 at 4:08 PM

0 · Reply

MicrocapCowboy Mar. 18 at 5:39 PM

0 · Reply

MOONMAN22 Mar. 17 at 6:46 PM

$APVO Holding & accumulating.

0 · Reply

MicrocapCowboy Mar. 17 at 1:20 PM

$APVO we are close...oh so close

0 · Reply

BLOCKS77 Mar. 13 at 10:26 PM

$APVO

0 · Reply

AZOZ Mar. 13 at 1:07 PM

$APVO Oversold swing idea 💡

0 · Reply

Traildog19 Mar. 12 at 1:23 PM

1 · Reply

zzzzzzzzzzzxxx Mar. 12 at 8:25 AM

$TAOP shorting both $APVO welcome mo

0 · Reply

ShadowSnake Mar. 11 at 8:36 PM

$APVO was there an offering I missed?

1 · Reply

BLOCKS77 Mar. 11 at 7:21 PM

$APVO Holding. Avg down. LFG.

0 · Reply

Quagglerock Mar. 11 at 6:38 PM

$APVO Additionally, I hope the shorts keep dicking around with this one and get their asses handed to them at some point.

1 · Reply

MicrocapCowboy Mar. 11 at 6:29 PM

$APVO market cap is absolutely insane with this latest dip. The ratio of the current price to the intrinsic value is roughly 1:1000.

0 · Reply

DonZulu Mar. 11 at 6:17 PM

$APVO 15$ avg 20-30$ coming few months. Hang on. No point selling here

0 · Reply

Quagglerock Mar. 11 at 4:28 PM

$APVO Good grief. I’ve been in this one on and off for 5 years now. Don’t think I’ve ever seen a company with so much potential that seemingly fumbles the ball on every handoff! Eight assets that all show promise with the lead asset positioned to completely disrupt big pharma’s cancer landscape and the market cap is $6 million? Unbelievable. At this point, why not just stop the madness and auction off assets and patents for a mere $50 million and call it a very expensive learning lesson?

1 · Reply

onlyfactshere Mar. 11 at 3:44 PM

$APVO I dont short but when I do…

0 · Reply

zzzzzzzzzzzxxx Mar. 11 at 3:28 PM

$APVO below 1 soooon

1 · Reply

zzzzzzzzzzzxxx Mar. 11 at 2:38 PM

$APVO shorting like a boss...no momo garbage real call

1 · Reply

zzzzzzzzzzzxxx Mar. 11 at 1:55 PM

$APVO I told you short wiyh me $TAOP

0 · Reply

zzzzzzzzzzzxxx Mar. 11 at 4:25 AM

$APVO straing to Penny warrants coming fornyour money

0 · Reply

BillionerOfKing Mar. 11 at 3:42 AM

$APVO Current Stock Price: $5.20

0 · Reply

ShadowSnake Mar. 10 at 10:56 PM

$APVO was the data that bad?

0 · Reply

BLOCKS77 Mar. 10 at 8:47 PM

$APVO Averaged down today. 🤞

0 · Reply

Market Cap	4.66M
Revenue (ttm)	0.00
Net Income (ttm)	-24.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	29,900
Avg Vol	194,000
Day's Range	N/A - N/A
Shares Out	998,000.00
Stochastic %K	31%
Beta	1.44
Analysts	Sell
Price Target	$21.00